Specificity
Human CD51
CD51 represents the 150 kDa integrin alpha V chain that associates with integrin beta 3 (CD61) to form the CD51/CD61 vitronectin receptor on endothelial cells, certain activated leukocytes, NK cells, macrophages, neutrophils and platelets. CD51 is the most promiscuous integrin a subunit; it can form heterodimers with the beta 1 (CD29), beta 3 (CD61), beta 5, beta 6 and beta 8 subunits in various tissues. CD51/CD61 acts as an activation-independent receptor for platelet attachment and spreading on vitronectin and other RGD-containing proteins, including matrix components. It also mediates leukocyte-endothelial cell adhesion via interaction with CD31.1-4
Preparation and Storage
The purified antibody (UNLB) is supplied as 0.1 mg purified immunoglobulin in 1.0 mL of 100 mM borate buffered saline, pH 8.0. Store at 2-8 degree C.
The fluorescein (FITC) conjugate is supplied as 100 tests in 1.0 mL of PBS/NaN3. Store at 2-8 degree C.
The R-phycoerythrin (R-PE) is supplied as 100 tests in 1.0 mL of PBS/NaN3 and a stabilizing agent. Store at 2-8 degree C. Do not freeze!
Protect conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.
Other Notes
Small volumes of anti-CD51 (Integrin alpha V) antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Product References and Citations for
anti-CD51 (Integrin alpha V) antibody
1. Knapp, W., B. Dorken, W.R. GIlks, E.P. Rieber, R.E. Schmidt, H. Stein, A.E.G.K. Von dem Borne, eds. 1989. Leukocyte Typing IV: White Cell Differentiation Antigens, Oxford University Press, Oxford.
2. Barclay, A.N., M.H. Brown, S.K.A. Law, A.J. McKnight, M.G. Tomlinson, and P.A. van der Merwe, eds. 1997. The Leukocyte Antigens Facts Book, 2nd Edition, CD51 Section, Academic Press, New York, p. 271.
3. Keiffer, N., and D.R. Phillips. 1990. Annu. Rev. Cell. Biol. 6:329.
4. Ginsberg, M.H., D. Xiaoping, T.E. O'Toole, J.C. Loftus, and E.F. Plow. 1993. Thromb. Haemost. 70:87.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our
Terms & Conditions page for more information.